Business context and reporting period
Accendra Health, Inc. (NYSE: ACH) filed this Form 8-K regarding an NYSE continued-listing deficiency. The Company received the NYSE notice on October 6, 2026; the related press release was dated October 9, 2026.
Financial and operating metrics
This filing provides no revenue, earnings, cash flow, margin, debt, or liquidity figures. It reports that the stock’s average closing price was below $1.00 per share over a consecutive 30-trading-day period.
Material changes and listing status
The NYSE notified the Company that it was not in compliance with Section 802.01C of the NYSE Listed Company Manual. The notice does not immediately affect the Common Stock’s NYSE listing, provided the Company continues to meet other applicable listing requirements. The filing describes no change to business operations or SEC reporting obligations.
Outlook, risks, and required actions
The Company said it would consider available alternatives to regain compliance and intends to notify the NYSE within 10 business days that it plans to cure the deficiency. It has six months from receipt of the notice to do so. Compliance may be regained if, on the last trading day of a calendar month during the cure period or on its final day, the stock closes at or above $1.00 and its average closing price over the preceding 30 trading days is also at or above $1.00. Failure to regain compliance could put the listing at risk; the filing does not specify which cure alternative the Company may pursue.
Key facts for investors to verify
- Whether the Company notified the NYSE of its intent to cure within the required 10 business days.
- Whether the stock meets both the $1.00 closing-price and 30-trading-day average tests at an applicable measurement date.
- Any subsequent NYSE notices, announced cure actions, or updates on continued-listing status.
- The related October 9, 2026 press release, furnished as Exhibit 99.1.